Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

699
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
699
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

149
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
149
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

474
Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
474
Blood Transfusion and Agglutination02:45

Blood Transfusion and Agglutination

13.6K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
13.6K
Hemoglobin01:24

Hemoglobin

6.8K
Hemoglobin is a globular protein made up of four subunits. Two of these subunits are alpha chains, and the other two are beta chains. Each subunit contains a molecule of heme, which has an iron atom and can bind to oxygen. When an oxygen molecule binds to one heme group, it changes the shape of hemoglobin, making it easier for the other heme groups to bind oxygen as well.
When all four heme groups are bound to oxygen, the resulting molecule is called oxyhemoglobin. As a result, arterial blood...
6.8K
Gene Therapy00:59

Gene Therapy

27.1K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-genotoxic transplantation and in vivo selection through epitope editing.

Nature·2026
Same author

AAV-mediated delivery of CRISPR/Cas9 targeting conserved overlapping ORFs efficiently suppresses HBV replication in hepatocyte models.

Biotechnology reports (Amsterdam, Netherlands)·2026
Same author

Establishment of a human induced pluripotent stem cell line MUi036-A from healthy male CD34<sup>+</sup> hematopoietic stem/progenitor cells.

Stem cell research·2026
Same author

Optimized lentivirus-derived virus-like particles for efficient delivery of Cas9-based genome editors.

Nucleic acids research·2026
Same author

Establishment of MURAi007-A, a human induced pluripotent stem cell line from a patient with inherited retinal dystrophy carrying compound heterozygous mutations in the PNPLA6 gene.

Stem cell research·2026
Same author

Activation of farnesoid X receptor inhibits TMEM16A-mediated chloride secretion in renal collecting duct cells and retards renal cyst progression.

American journal of physiology. Renal physiology·2026

Related Experiment Video

Updated: Dec 9, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K

Innovative Therapies for Hemoglobin Disorders.

Karine Sii-Felice1, Olivier Negre1,2,3, Christian Brendel2

  • 1Division of Innovative Therapies and UMR 1184 IMVA-HB, Institute of Biology François Jacob, CEA, INSERM, Paris-Saclay University, CEA Fontenay aux Roses, 18 route du Panorama, 92260, Fontenay aux Roses, France.

Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
|September 8, 2020
PubMed
Summary

Gene therapy for beta-thalassemia has advanced significantly, with new lentiviral vectors and gene editing tools offering hope for a definitive cure for hemoglobin disorders.

More Related Videos

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.1K
Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats
09:47

Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats

Published on: June 14, 2024

943

Related Experiment Videos

Last Updated: Dec 9, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.8K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

20.1K
Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats
09:47

Author Spotlight: Utilizing Next-Generation Polymerized Human Hemoglobin for Improved Donor Lung Evaluation and Preservation in Rats

Published on: June 14, 2024

943

Area of Science:

  • Hematology
  • Gene Therapy
  • Molecular Biology

Background:

  • Hematopoietic stem cell (HSC) gene therapy for beta-globin disorders faces challenges including selection of corrected HSCs and achieving adequate transgene expression.
  • Over 40 years of research have led to understanding disease mechanisms, developing animal models, and creating gene transfer vectors.

Purpose of the Study:

  • To review the development of advanced gene therapy products for hemoglobin disorders.
  • To highlight recent technological innovations and their potential for future clinical trials.

Main Methods:

  • Review of lentiviral gene therapy vectors expressing beta-globin variants or targeting gamma-globin repressors.
  • Exploration of emerging technologies like gene editing and induced pluripotent stem cells.

Main Results:

  • The first gene therapy product for beta-thalassemia was authorized in 2019.
  • Several lentiviral vector-based therapies are in clinical testing, with more expected to diversify treatment options.
  • New tools like gene editing and iPSCs are under investigation for alternative therapeutic products.

Conclusions:

  • Significant progress has been made in gene therapy for hemoglobin disorders, with ongoing innovation promising further advancements.
  • Advanced technologies, including gene editing, hold potential for definitive cures for severe hemoglobin conditions.
  • Hemoglobin disorders serve as a crucial model for evaluating novel gene therapy technologies.